FDA approves Boehringer-Lilly drug for type-2 diabetes patients

Reuters

(Reuters) - The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and privately held Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said. The drug, Glyxambi, combines empagliflozin and linagliptin, commonly prescribed diabetes medications which are manufactured by Lilly and Boehringer. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)